Cardiff Oncology, Inc. insider trading
Every open-market purchase and sale by Cardiff Oncology, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Cardiff Oncology, Inc.’s insiders pay?
From April 16, 2012 to July 16, 2026, 19 insiders reported 51 open-market purchases and 2 sales not made under a pre-set plan in Cardiff Oncology, Inc. Twelve months after each purchase was reported, the shares were −54.7% against the S&P 500 on average (median −62.7%), over 19 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −75.1% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on December 4, 2012 into $1,292 by November 2, 2026, −13.7% a year. It held shares 40% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $22,391 (+6.0% a year), and held throughout $68,086 (+14.8%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Pace Gary W | Director | 13 | −78.9% (5) | 0% | 0 | — | July 16, 2026 |
| Tennant Stanley | Director | 5 | −14.6% (2) | 0% | 0 | — | December 19, 2016 |
| Bridger Management, LLC | 10% owner | 4 | −32.1% (3) | 0% | 0 | — | November 15, 2016 |
| Armitage James O | Director | 3 | −84.7% (1) | 0% | 0 | — | October 11, 2022 |
| Cerrone Gabriel | Director | 3 | — | — | 0 | — | August 20, 2012 |
| Levine James E. | Chief Financial Officer | 3 | −65.2% (1) | 0% | 0 | — | December 18, 2024 |
| Markin Rodney S | Director | 3 | −90.9% (1) | 0% | 0 | — | March 29, 2021 |
| Adams Thomas Phd | Director | 1 | — | — | 1 | −45.4% (1) | May 18, 2020 |
| Erlander Mark | Chief Executive Officer | 2 | — | — | 0 | — | November 29, 2022 |
| Jacob Gary S | Director | 2 | −91.9% (1) | 0% | 0 | — | March 23, 2021 |
| Mohindru Mani | Chief Executive Officer | 2 | — | — | 0 | — | July 16, 2026 |
| Tannenbaum Renee P | Director | 2 | −66.3% (1) | 0% | 0 | — | December 16, 2024 |
| White Lale | Director | 2 | — | — | 0 | — | September 20, 2022 |
| Zaniboni Steve | CFO | 2 | −14.4% (1) | 0% | 0 | — | August 12, 2015 |
| Brancaccio John P | Director | 1 | −91.5% (1) | 0% | 0 | — | March 22, 2021 |
| Hunter Robert Merrill | 10% owner | 1 | — | — | 0 | — | April 16, 2012 |
| Kelemen Vicki | Exec. VP and COO | 0 | — | — | 1 | −104.9% (1) | November 25, 2020 |
| Mignone Roberto | 10% owner | 1 | −0.2% (1) | 0% | 0 | — | February 27, 2015 |
| Schuh Antonius | CEO | 1 | −14.4% (1) | 0% | 0 | — | August 12, 2015 |
When several insiders traded Cardiff Oncology, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Cardiff Oncology, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 4 buying crowds with six months of prices, it averaged −32.3% against the index. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| September 30, 2021 | 2 buying | −18.1% | −68.7% | −61.4% |
| March 31, 2021 | 4 buying | −36.5% | −39.6% | −90.6% |
| August 31, 2015 | 4 buying | +2.4% | −3.5% | −29.5% |
| March 31, 2015 | 2 buying | +48.8% | −17.5% | −33.4% |